Abstract
To evaluate the outcome of differentiated thyroid cancer (DTC) patients with biochemical persistence of disease (BP) after initial treatment (total thyroidectomy with or without lymph node dissection (LND) and thyroid remnant ablation). BP was defined as suppressed thyroglobulin (Tg) levels <1 ng/ml and rhTSH-stimulated thyroglobulin (St-Tg) >1ng/ml, with no evidence of structural disease. Structural persistence/recurrence (SPR): clinically identifiable disease. We reviewed 278 records of DTC patients. Tg-Ab positive patients (n = 73) were excluded and 32 were included in the analysis (median age 45 years, range 18–77 years); risk of recurrence ATA was: low in 38 %, Intermediate in 47 %, and high in 15 % of patients. All subjects had Tg levels <1 ng/ml under thyroid hormone therapy. Patients were divided into three groups: Group 1: St-Tg 1–2 ng/ml, n = 6; Group 2: St-Tg 2–10 ng/ml, n = 17; Group 3: St-Tg > 10 ng/ml, n = 9. In 5/32 (16 %) patients, SPR was observed after a median follow-up of 6 years (range 2–23 years). In Group 1: all patients were considered with no evidence of disease after a median follow-up of 2 years (range 1–2.5 years). In Group 2: 13/17 (76.5 %) patients continued with only a BP after a median follow-up of 4 years (range 2–10 years) and 4/17 (23.5 %) patients with intermediate risk of recurrence had a structural persistence (lymph nodes metastasis) diagnosed between 1 and 3.5 years after initial assessment. Following LND, all of them remained with BP after a median of 2 years (range 1.5–5 years). In Group 3: 8/9 (89 %) patients had BP after a median follow-up of 7 years (range 2–23 years) and 1/9 (11 %) had a SPR diagnosed 28 months after initial assessment, LND was indicated but he continued with BP, 5 years after the second surgery. Most patients with DTC and BP present an indolent course of the disease. In these patients the diagnosis of the structural recurrence did not change the outcome because all of them continued with BP.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Thyroid 19, 1167 (2009)
F. Pitoia, L. Ward, N. Wohllk, C. Friguglietti, E. Tomimori, A. Gauna, R. Camargo, M. Vaisman, R. Harach, F. Munizaga, S. Corigliano, E. Pretell, H. Niepomnizcze, Arq. Bras. Endocrinol. Metabol. 53, 884 (2009)
F. Pitoia, F. Bueno, C. Urciuoli, E. Abelleira, G. Cross, R.M. Tuttle, Thyroid (2013). doi:10.1089/thy.2013.0011
F. Vaisman, D. Momesso, D.A. Bulzico, C.H. Pessoa, F. Dias, R. Corbo, M. Vaisman, R.M. Tuttle, Clin. Endocrinol. (Oxf). 77, 132 (2012)
M.G. Castagna, F. Maino, C. Cipri, V. Belardini, A. Theodoropoulou, G. Cevenini, F. Pacini, Eur. J. Endocrinol. 165, 441 (2011)
R.M. Tuttle, H. Tala, J. Shah, R. Leboeuf, R. Ghossein, M. Gonen, M. Brokhin, G. Omry, J.A. Fagin, A. Shaha, Thyroid 20, 1341 (2010)
B.R. Haugen, E.C. Ridgway, B.A. McLaughlin, M.T. McDermott, Thyroid 12, 37 (2002)
E.L. Mazzaferri, R.T. Kloos, J. Clin. Endocrinol. Metab. 87, 1490 (2002)
R.J. Robbins, J.T. Chon, M. Fleisher, S.M. Larson, R.M. Tuttle, J. Clin. Endocrinol. Metab. 87, 3242 (2002)
L. Wartofsky, Thyroid 12, 583 (2002)
A. David, A. Blotta, M. Bondanelli, R. Rossi, E. Roti, L.E. Braverman, L. Busutti, E.C. degli Uberti, J. Nucl. Med. 42, 1470 (2001)
F. Pacini, E. Molinaro, F. Lippi, M.G. Castagna, L. Agate, C. Ceccarelli, D. Taddei, R. Elisei, M. Capezzone, A. Pinchera, J. Clin. Endocrinol. Metab. 86, 5686 (2001)
B.R. Haugen, F. Pacini, C. Reiners, M. Schlumberger, P.W. Ladenson, S.I. Sherman, D.S. Cooper, K.E. Graham, L.E. Braverman, M.C. Skarulis, T.F. Davies, L.J. DeGroot, E.L. Mazzaferri, G.H. Daniels, D.S. Ross, M. Luster, M.H. Samuels, D.V. Becker, H.R. Maxon 3rd, R.R. Cavalieri, C.A. Spencer, K. McEllin, B.D. Weintraub, E.C. Ridgway, J. Clin. Endocrinol. Metab. 84, 3877 (1999)
R. Schulz, H. Bethäuser, L. Stempka, B. Heilig, A. Moll, M. Hüfner, Eur. J. Clin. Invest. 19, 459 (1989)
A.S. Alzahrani, G. Mohamed, A. Al Shammary, S. Aldasouqi, S. Abdal Salam, M. Shoukri, J. Endocrinol. Invest. 28, 540 (2005)
E. Baudin, C. Do Cao, A.F. Cailleux, S. Leboulleux, J.P. Travagli, M. Schlumberger, J. Clin. Endocrinol. Metab. 88, 1107 (2003)
J. Biko, C. Reiners, M.C. Kreissl, F.A. Verburg, Y. Demidchik, V. Drozd, Eur. J. Nucl. Med. Mol. Imaging 38, 123 (2011)
E.G. Black, M.C. Sheppard, R. Hoffenberg, Clin. Endocrinol. (Oxf). 27, 115 (1987)
A.L. Gutierrez Cardo, J.R. Rodriguez, I. Borrego Dorado, E. Navarro Gonzalez, J.L. Tirado, R. Vazquez Albertino, Rev. Esp. Med. Nucl. 26, 138 (2007)
S.H. Huang, P.W. Wang, Y.E. Huang, F.F. Chou, R.T. Liu, S.C. Tung, J.F. Chen, M.C. Kuo, J.R. Hsieh, H.H. Hsieh, Thyroid 16, 1273 (2006)
W.G. Kim, J.S. Ryu, E.Y. Kim, J.H. Lee, J.H. Baek, J.H. Yoon, S.J. Hong, E.S. Kim, T.Y. Kim, W.B. Kim, Y.K. Shong, J. Clin. Endocrinol. Metab. 95, 1169 (2011)
M. Ozata, S. Suzuki, T. Miyamoto, R.T. Liu, F. Fierro-Renoy, L.J. De Groot, J. Clin. Endocrinol. Metab. 79, 98 (1994)
F. Vaisman, H. Tala, R. Grewal, Thyroid 21, 1317–1322 (2011)
R.P. Padovani, E. Robenshtok, M. Brokhin, R.M. Tuttle, Thyroid 22, 778 (2012)
H. Tala, R.M. Tuttle, Clin. Oncol. 22, 419 (2010)
A. Miyauchi, T. Kudo, A. Miya, K. Kobayashi, Y. Ito, Y. Takamura, T. Higashiyama, M. Fukushima, M. Kihara, H. Inoue, C. Tomoda, T. Yabuta, H. Masuoka, Thyroid 21, 707 (2011)
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fabián, P., Erika, A., Hernán, T. et al. Biochemical persistence in thyroid cancer: is there anything to worry about?. Endocrine 46, 532–537 (2014). https://doi.org/10.1007/s12020-013-0097-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-013-0097-6